Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare Costs: Forty-Year Follow-Up of the CHA Study (Chicago Heart Association Detection Project in Industry)
- PMID: 28461414
- PMCID: PMC5476215
- DOI: 10.1161/CIRCULATIONAHA.116.026252
Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare Costs: Forty-Year Follow-Up of the CHA Study (Chicago Heart Association Detection Project in Industry)
Abstract
Background: We examined the association of cardiovascular health at younger ages with the proportion of life lived free of morbidity, the cumulative burden of morbidity, and average healthcare costs at older ages.
Methods: The CHA study (Chicago Heart Association Detection Project in Industry) is a longitudinal cohort of employed men and women 18 to 74 years of age at baseline examination in 1967 to 1973. Baseline measurements included blood pressure, cholesterol, diabetes mellitus, body mass index, and smoking. Individuals were classified into 1 of 4 strata of cardiovascular health: favorable levels of all factors, 0 factors high but ≥1 elevated risk factors, 1 high risk factor, and ≥2 high risk factors. Linked Medicare and National Death Index data from 1984 to 2010 were used to determine morbidity in older age. An individual's all-cause morbidity score and cardiovascular morbidity score were calculated from International Classification of Disease, Ninth Revision codes for each year of follow-up.
Results: We included 25 804 participants who became ≥65 years of age by 2010, representing 65% of all original CHA participants (43% female; 90% white; mean age, 44 years at baseline); 6% had favorable levels of all factors, 19% had ≥1 risk factors at elevated levels, 40% had 1 high risk factor, and 35% had ≥2 high risk factors. Favorable cardiovascular health at younger ages extended survival by almost 4 years and postponed the onset of all-cause and cardiovascular morbidity by 4.5 and 7 years, respectively, resulting in compression of morbidity in both absolute and relative terms. This translated to lower cumulative and annual healthcare costs for those in favorable cardiovascular health (P<0.001) during Medicare eligibility.
Conclusions: Individuals in favorable cardiovascular health in early middle age live a longer, healthier life free of all types of morbidity. These findings provide strong support for prevention efforts earlier in life aimed at preserving cardiovascular health and reducing the burden of disease in older ages.
Keywords: cardiovascular diseases; morbidity; mortality; prevention and control; risk factors.
© 2017 American Heart Association, Inc.
Figures
Comment in
-
Living Longer in Good Cardiovascular Health: Prevention and Wellness Makes Economic Cents.Circulation. 2017 May 2;135(18):1702-1704. doi: 10.1161/CIRCULATIONAHA.117.027960. Circulation. 2017. PMID: 28461415 No abstract available.
Similar articles
-
Cardiovascular health in young and middle adulthood and medical care utilization and costs at older age - The Chicago Heart Association Detection Project Industry (CHA).Prev Med. 2019 Feb;119:87-98. doi: 10.1016/j.ypmed.2018.12.024. Epub 2018 Dec 28. Prev Med. 2019. PMID: 30594534 Free PMC article.
-
Favorable Cardiovascular Health at Young and Middle Ages and Dementia in Older Age-The CHA Study.J Am Heart Assoc. 2019 Jan 8;8(1):e009730. doi: 10.1161/JAHA.118.009730. J Am Heart Assoc. 2019. PMID: 30590968 Free PMC article.
-
Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs.N Engl J Med. 1998 Oct 15;339(16):1122-9. doi: 10.1056/NEJM199810153391606. N Engl J Med. 1998. PMID: 9770560
-
[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. G Ital Cardiol (Rome). 2008. PMID: 18773746 Review. Italian.
-
Health Economics of Cardiovascular Disease in the United States.Circulation. 2024 Aug 6;150(6):419-421. doi: 10.1161/CIRCULATIONAHA.124.068295. Epub 2024 Aug 5. Circulation. 2024. PMID: 39102477 Review. No abstract available.
Cited by
-
Exploration of the association between new "Life's Essential 8" with hyperuricemia and gout among US adults.Qual Life Res. 2024 Sep 21. doi: 10.1007/s11136-024-03777-y. Online ahead of print. Qual Life Res. 2024. PMID: 39305437
-
Improving Cardiovascular Disease Primary Prevention Treatment Thresholds in a New England Health Care System.JACC Adv. 2024 Sep 6;3(10):101257. doi: 10.1016/j.jacadv.2024.101257. eCollection 2024 Oct. JACC Adv. 2024. PMID: 39290815 Free PMC article.
-
Patients' health care resources utilization and costs estimation across cardiovascular risk categories: insights from the LATINO study.Health Econ Rev. 2024 Sep 12;14(1):73. doi: 10.1186/s13561-024-00550-2. Health Econ Rev. 2024. PMID: 39264520 Free PMC article.
-
Population Health and Artificial Intelligence.JACC Adv. 2024 Jul 4;3(8):101092. doi: 10.1016/j.jacadv.2024.101092. eCollection 2024 Aug. JACC Adv. 2024. PMID: 39055275 Free PMC article.
-
Risk-stratified analysis of long-term clinical outcomes and cumulative costs in Finnish patients with recent acute coronary syndrome or coronary revascularization: a 5-year real-world study using electronic health records.Eur Heart J Open. 2024 Jun 18;4(4):oeae049. doi: 10.1093/ehjopen/oeae049. eCollection 2024 Jul. Eur Heart J Open. 2024. PMID: 38988674 Free PMC article.
References
-
- Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–944. - PubMed
-
- Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC, Jr, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP American Heart Association Advocacy Coordinating C, Council on Cardiovascular Disease in the Y, Council on the Kidney in Cardiovascular D, Council on E, Prevention, Council on Cardiovascular N, Council on A, Thrombosis, Vascular B, Council on Clinical C and Stroke C. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011;124:967–990. - PubMed
-
- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586–613. - PubMed
-
- U S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion--Healthy People 2010. Nasnewsletter. 2000;15:3. - PubMed
-
- Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012–2018. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
